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ABSTRAK 
 
Orthosiphon stamineus ialah ubatan tempatan popular yang digunakan untuk 
merawat pelbagai penyakit termasuk diabetes melitus. Kajian ini dijalankan untuk 
mengkaji aktiviti antidiabetik, mekanisma tindak balas dan kesan toksik ekstrak 
piawai daun Orthosiphon stamineus. Daun Orthosiphon stamineus diekstrak 
menggunakan (etanol : air)  95%, 75%, 50% dan 25% v/v, masing – masing. Hanya 
ekstrak etanol 50% (1000 mg/kg) menurunkan paras glukosa darah tikus yang 
diberikan beban glukosa subkutaneus sebanyak 200 mg/kg. Walaubagaimanapun, 
ekstrak etanol 50% gagal menurunkan paras glukosa darah tikus diabetik aruhan-
STZ. Pengekstrakan cecair – cecair ekstrak etanol 50% menghasilkan fraksi – fraksi 
etil asetat, n-butanol dan air. Hanya fraksi etil asetat (ESF) (1000 mg/kg) merencat 
kenaikan paras glukosa darah tikus yang diberi beban glukosa. ESF seterusnya 
disisihkan kepada dua subfraksi ESF-1 dan ESF-2, menggunakan kromatografi turus 
kilat kering. Keputusan menunjukkan rawatan dengan fraksi ESF-2 merencat 
kenaikan glukosa darah lebih daripada  rawatan dengan ESF-1. Pemberian ekstrak 
etanol 50% pada dos 1000 mg/kg dua kali sehari selama empat belas hari 
menurunkan paras glukosa darah tetapi tidak meningkatkan paras insulin tikus 
diabetik aruhan-STZ. Kajian in vitro menunjukkan ekstrak etanol 50% O. stamineus 
merencat aktiviti α-glukosidase dan α-amilase dalam ciri kebergantungan kepada 
dos. Kajian  in vivo menunjukkan pemberian secara oral ekstrak etanol 50% (250, 
500 dan 1000 mg/kg) merencat kenaikan paras glukosa darah tikus yang diberi beban 
kanji dan sukrosa secara oral, masing – masing,  yang seterusnya mencadangkan 
ekstrak mungkin merencat aktiviti α-glukosidase dan α-amilase di dalam saluran 
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pencernaan dan berguna dalam merawat hiperglisemia postprandial. Pembaikan 
dalam kerintangan terhadap insulin dengan pemberian oral ekstrak etanol 50% O. 
stamineus juga dikaji secara in vivo. Rawatan harian ekstrak etanol 50% (1000 
mg/kg) selama empat belas hari dalam tikus rintang insulin aruhan emulsi tinggi 
lemak menyebabkan penurunan dalam paras glukosa dan insulin plasma. Rawatan 
yang sama dalam tikus diabetik aruhan-STZ menyebabkan kenaikan dalam respons 
pemberian eksogenus insulin tindakan jangka pendek yang mencadangkan rawatan 
ini telah menurunkan kerintangan terhadap insulin dalam tikus. Dalam kajian 
ketoksikan akut, pemberian secara oral ekstrak etanol 50% (5000 mg/kg) tidak 
menyebabkan sebarang tanda ketoksikan dan mortaliti yang mencadangkan bahawa 
LD50 adalah lebih tinggi daripada 5000 mg/kg. Dalam kajian ketoksikan sub-kronik, 
pemberian ekstrak etanol 50% pada dos 1250, 2500 dan 5000 mg/kg setiap hari 
selama 28 hari  dalam tikus tidak menyebabkan sebarang tanda dan simptom toksik 
yang boleh diperhatikan, perubahan  dalam parameter hematologi atau rupa secara 
kasar organ dalaman yang mencadangkan bahawa ekstrak ini adalah tidak toksik. 
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ANTIDIABETIC ACTIVITY AND TOXICITY STUDY OF ORTHOSIPHON 
STAMINEUS BENTH ETHANOLIC EXTRACTS 
 
 
ABSTRACT 
 
Orthosiphon stamineus is a popular folk medicine used for the treatment of many 
diseases including diabetes mellitus. This study was under taken to investigate the 
antidiabetic activity, mechanism of actions and toxicity study of standardized O. 
stamineus leaves extract.  Leaves of O. stamineus were extracted with 95%, 75%, 
50%, and 25% (ethanol : water) v/v respectively. Only the 50% ethanolic extract 
(1,000 mg/kg), reduced the blood glucose level of rats loaded subcutaneously with 
200 mg/kg glucose. However, the 50% ethanolic extract failed to lower the blood 
glucose level of the STZ-induced diabetic rats. Liquid-liquid extraction of the 50% 
ethanol extract produced ethyl acetate, n-butanol and water fractions. Only ethyl 
acetate fraction (ESF) (1,000 mg/kg) inhibited the rise of blood glucose level of 
glucose loaded rats. ESF was then fractionated further into two sub-fractions ESF-1 
and ESF-2, using a dry flash column chromatography.  The results showed that 
treatment with ESF-2 fraction inhibited the rise of blood glucose more than ESF-1. 
Administration of 50% ethanolic extract of O. stamineus at the doses of 1,000 mg/kg 
twice daily for fourteen days decreased blood glucose level but not increased the 
insulin level of STZ-induced diabetic rats.  In vitro studies showed that 50% ethanolic 
extract of O. stamineus inhibited α-glucosidase and α-amylase activities in a dose-
dependent manner. In vivo study showed that 50% ethanolic extract of (250, 500 and 
1000 mg/kg) treatment inhibited the rise of blood glucose level of oral starch and 
sucrose loaded rats respectively which suggest the extract may be useful for treatment 
of postprandial hyperglycemia. The improvement of insulin resistance by an oral 
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administration of 50% ethanol extract of O. stamineus was also investigated in vivo. 
Daily treatment of 50% ethanol extract (1,000mg/kg) for 14 days in high fat 
emulsion-induced insulin resistance rats caused reduction in both plasma glucose and 
insulin levels. Similar treatment to STZ-induced diabetic rats caused an increase in 
the response of exogenous administration of short-acting insulin which suggests that 
the treatment had reduced the insulin resistance in the rats. In the acute toxicity study, 
oral administration of 50% ethanol extract (5,000 mg/kg) did not cause any sign of 
toxicity or mortality which suggest the LD50 is higher than 5,000 mg/kg. In sub-
chronic toxicity study, administration of 50% ethanol extract at 1250, 2500, and 5000 
mg/kg daily for 28 days in rats did not cause any observable toxic sign and symptom 
or changes in hematological parameters or gross appearance of the internal organs 
which suggest this extract is not toxic. 
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CHAPTER ONE: Introduction 
 
1.1. History of traditional medicines  
Traditional medicines, particularly herbal remedies, have been used for thousands of 
years in maintaining health as an alternative to or in conjunction with modern 
medicines. People in developed countries spend considerable amounts of money on 
herbal products. The majority of the world’s populations in developing countries take 
herbal medicines to meet their health needs, following traditional beliefs and 
practices adopted by their elders and ancestors. Plants are widely used as medicines 
and there are a number of pure isolated compounds, such as taxol and artemisinin, 
which are already in use clinically. Herbal products are less potent and, in general, 
cause fewer adverse reactions than pharmaceuticals and their use can play an 
important role in the reduction of national spending (Llya et al., 2002).  
 
Recent studies on the biologically active constituents of medicinal plants have made 
it possible to develop new drugs for clinical use (Dhawan, 1982). When natural 
products serve as the lead compounds in drug development, the medicinal drugs 
developed via this process are chemically synthesized. However, the interest shown 
by international bodies like the World Health Organization (WHO) towards 
traditional plants is a sign of global reawakening regarding the contribution such 
plants have as important alternatives in health care. It has been realized that if there 
are to be any real improvements in health care, especially in the underserved 
populations of the world, there will have to be an optimal use of all available 
resources and there is no doubt that medicinal plants are one of them. In some 
countries traditional herbal medicines have been placed on the same footing as 
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modern medicines (Fransworth and Bingel, 1977). In Asia, countries like China, 
Japan, Korea and India are among the foremost examples where traditional herbal 
medicines and remedies have been officially recognized (Dzulkifli et al., 1993). 
 
1.2. The plant, Orthosiphon stamineus Benth 
1.2.1. Botanical aspects 
Scientific name   : Orthosiphon stamineus, Benth. 
Synonym       : Ocimum aristatum Bl., Orthosiphon aristatum (Blume)          
Common name            : Java tea. 
Local name                  : Misai Kucing, Kumis Kucing. 
Part used                      : Leaves and stems. 
 
 
Figure 1.1. The plant O. stamineus Benth (Mohd and Mustafa, 1994). 
 
O. stamineus first began to interest researchers as early as the beginning of the 
twentieth century when this plant was introduced to Europe, where it became a 
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popular herbal tea. In Malaysia, it is also appreciated for its elegant, unique flowers 
and it is commonly seen growing in many gardens. O. stamineus is an herbaceous 
shrub that grows to a height of 1.5 m (Mohd and Mustafa, 1994). The leaves are 
arranged in opposing pairs. They are simple, green and glabrous, with a lancelet leaf 
blade and a serrated margin. The leaf apices are acuminate with an acute leaf base. 
The petiole is relatively short, about 0.3 cm in length, and reddish purple in color, 
with erect and profuse branches (Mohd and Mustafa, 1994). This plant is one of the 
most popular traditional folk medicines and is extensively used in Southeast Asia for 
the treatment of a wide range of diseases. In Malaysia, this plant is used in the form 
of a decoction to treat diabetes and catarrh of the bladder, and as a diuretic (Bwin and 
Gwan, 1967). In Vietnam, it is used for treating urinary lithiasis, edema, eruptive 
fever, influenza, hepatitis, jaundice and biliary lithiasis (Eisai, 1995). In Myanmar, 
the plant is used to alleviate diabetes and urinary tract and renal diseases (WHO, 
1970), and in Indonesia it is used for rheumatism, diabetes, hypertension, syphilis, 
renal calculus and gallstones, amongst others (Bwin and Gwan, 1967). 
 
1.2.2. Literature review on O. stamenius Benth. 
In 2007, Abdullaha et al. reported that standardized extracts of O. stamineus have no 
observable acute effects on experimental animals at 5000 mg/kg and are therefore 
non-toxic. Olah et al. (2003) reported that the ethanolic extract of O. stamineus has 
high contents of sinensetin, eupatorin, rosmarinic-, cichoric- and caffeic-acids and a 
good pharmacological action on diuretic and uricosuric in rats. In another study,     
O. stamineus aqueous extracts were found to be useful in the control of diabetes 
mellitus as they markedly reduced hyperglycemia in STZ-induced diabetic rats, 
decreased plasma triglyceride and increased plasma high-density lipoprotein (HDL) 
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cholesterol concentrations (Sriplang et al., 2007). The methanolic extracts of this 
plant have been shown to inhibit nitric oxide production in macrophage-like cells 
(Awale et al., 2003a and b). A study conducted by Chin et al. (2009) showed that a 
methanolic extract of O. stamineus leaf exerted a selective effect on aminopyrine N-
demethylase, Uridine 5'-diphospho-glucuronosyltransferase (UDP), 
glucoronosyltransferase (UGT) and glutathione-S-transferase (GST) activities. The 
activities of GST and UGT were highly sensitive and easily inducible by methanolic 
extracts of O. stamineus leaves compared to aminopyrine N-demethylase activity. 
 
O. stamineus has been reported to contain several active constituents such as 
terpenoids and polyphenols (Tezuka et al., 2000). Most of the therapeutic effects and 
health benefits of O. stamineus have been mainly ascribed to its polyphenolic 
contents (Akowuah et al., 2005). The latter are the most dominant constituents of the 
plant’s leaves (Hollman and Katan, 1999). Akowuah et al (2005) demonstrated the 
presence of rosmarinic acid (RA), sinensetin (SIN), eupatorin (EUP) and 3’-hydroxy-
5,6,7,4’-tetramethoxyflavone (TMF) in the leaves of O.  stamineus (Figs. 1.2, 3, 4 
and 5). Moreover, the RA contents of this plant were also reported by Tezuka et al. 
(2000). Lipophilic flavonoids isolated from O. stamineus have been found to possess 
a remarkable free radical-scavenging activity towards the diphenylpicrylhydrazyl 
radical, adding to their abilities to inhibit the enzyme 15-lipoxygenase from 
soybeans, a model for mammalian 15-lipoxygenase (Lyckander and Malterud, 1996). 
Researchers have also indicated that the flavones SIN and TMF, isolated from O. 
stamineus, exhibit a potent diuretic activity in rats (Schut and Zwaving, 1993). On 
the other hand, the diterpenes isolated from Orthosiphon sp. have been shown to 
exhibit antiproliferative activities on the rat thoracic aorta (Tezuka et al., 2000; 
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Awale et al., 2001; Awale et al., 2002a and b). Furthermore, studies on these 
diterpenes revealed their substantial capabilities of antagonizing the actions of nitric 
oxide (Awale et al., 2004) and inhibiting tumor promoter of 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced inflammation in mouse ears 
(Masuda et al., 1992). Recent studies have also shown that O. stamineus extracts 
retain a notable hepatoprotective action against CCl4-induced hepatopathy (Yam et 
al., 2007), anti-inflammatory and non-narcotic analgesic activities (Yam et al., 2008) 
and antipyretic effects in a yeast-induced increase in body temperature (Yam et al., 
2009). 
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Figure 1.2. Molecules of Rosmarinic Acid (RA) (Akowuah et al, 2004). 
 
 
 
 
Figure 1.3 Molecules of Sinensetin (SIN) (Akowuah et al, 2004). 
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Figure 1.4. Molecules of Eupatorin (EUP) (Akowuah et al, 2004). 
 
 
 
 
 
 
Figure 1.5. Molecules of 3-hydroxy-5,6,7,4 – tetramethoxyflavone (TMF) (Akowuah 
et al, 2004). 
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1.3. Diabetes mellitus 
Historically, diabetes mellitus is one of the oldest diseases known to mankind. It was 
first mentioned in the Ebers Papyrus (Egypt 1500 BC) and ‘honey urine’ was noted 
by Sushrutha in India in 400 BC. By the first century of the Christian era this disease 
was well known, both in Roman writings and in Chinese and Japanese writings 
(Distiller, 1980). The word ‘diabetes’ was first coined by the Greeks. It means a 
passing-through of water. They described it as a ‘melting of flesh into water’, 
meaning urine. The Latin word ‘mel’, which means honey, was used and the disease 
came to be known as diabetes mellitus or passing of honeyed urine. This is still the 
full name of the disease – diabetes mellitus (Distiller, 1980). 
 
In 1997 an estimated 15.7 million Americans, or 5.9% of the population, had 
diabetes mellitus (Siri et al., 2004). Among this group, 10.3 million were diagnosed 
diabetics and 5.4 million were undiagnosed (Siri et al., 2004). Diabetes is a complex 
and costly disease that can affect almost every organ in the body and result in 
devastating consequences. Diabetes is the leading cause of non-traumatic lower 
extremity amputations, renal failure and blindness in working-age adults and it is 
also a major cause of premature mortality, stroke, cardiovascular disease, peripheral 
vascular disease, congenital malformation, perinatal mortality and disability 
(Michael and Linda, 2000). 
 
 Before 1979, no standard classification scheme or uniform diagnostic criteria existed 
for diabetes. In 1979-1980, the National Diabetes Data Group (NDDG) in the United 
States and the World Health Organization (WHO), in parallel efforts, reviewed the 
available scientific knowledge and developed and disseminated recommendations for 
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the classification and diagnosis of diabetes. These recommendations were accepted 
worldwide and significantly contributed to a tremendous expansion in the knowledge 
about diabetes (Jack et al., 2000). During 1995-1997, the international expert 
committee on the diagnosis and classification of diabetes mellitus convened and 
revised the NDDG-WHO recommendations for the classification and diagnosis of 
diabetes and also made recommendations for testing of diabetes. The committee 
recommended that diabetes be classified as type I and type II. The type I designation 
was chosen to replace the designation of insulin-dependent diabetes mellitus 
(IDDM), also called juvenile-onset diabetes. The type II designation replaced the 
designation of non-insulin-dependent diabetes mellitus (NIDDM) also called adult-
onset diabetes (Jack et al., 2000).  
 
1.3.1. Type I diabetes (insulin-dependent diabetes mellitus, IDDM) 
Type I diabetes accounts for 5-10% of all diagnosed cases of diabetes. It is one of the 
most frequent chronic diseases in children. About 40% of people with type I diabetes 
are younger than 20 years of age, and about 30,000 new cases of type I diabetes 
occur each year in USA (Jack et al., 2000). However, about 9% of diabetics in North 
America and 20% of diabetics in Scandinavian countries have type I diabetes. It is a 
catabolic disorder in which circulating insulin is virtually absent, plasma glucagons 
are elevated, and pancreatic β-cells fail to respond to all known insulinogenic stimuli. 
In the absence of insulin the three main target tissues of insulin (liver, muscle and 
fat) not only fail to appropriately take up absorbed nutrients but they also fail to 
continue to deliver glucose, amino acids and fatty acids into the bloodstream from 
their respective storage depots (Francis and David, 2004).  
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The onset of type I diabetes is often abrupt, with symptoms of thirst, polyuria, weight 
loss and a tendency for the liver to produce ketones. Ketone production can be 
excessive and lead to ketoacidosis as the presenting clinical picture. The primary 
defect is insulin deficiency due to disease of the beta cells of the islets of 
Langerhans, and ketoacidosis results from severe insulin deficiency (John and 
Jeremy, 1983). Genetic factors account for about one third of the susceptibility to 
type I diabetes, the inheritance of which is polygenic. Over 20 different regions of 
the human genome show some linkage with type I diabetes, but most interest has 
been focused on the human leucocyte antigen (HLA) region within the major 
histocompatibility complex on the short arm of the chromosome. This locus is 
designated IDDM (Christopher et al., 1999).  
 
1.3.2. Type II diabetes (non-insulin-dependent diabetes mellitus, NIDDM) 
Type II diabetes, characterized as non-insulin-dependent or insulin-resistant, can be 
present for months or years with few or no symptoms and is the type that occurs in 
middle and old age. Sufficient glucose enters cells to permit adequate energy 
production for most situations, and the main problem is excess glucose outside the 
cells rather than a shortfall inside. Such patients are often overweight (which 
increases cellular resistance to insulin) and do not usually become ketotic 
(Wiernsperger and Bailey, 1999). They can often be treated successfully with a diet 
that avoids immediate hyperglycemia by limiting the intake of low molecular weight 
carbohydrates and by losing excess weight (Derek and Andrew, 1994). Genetic 
factors are more important in the etiology of type II than type I diabetes, as shown by 
studies in monozygotic twins where concordance rates for type II diabetes were 
found to approach 95% (Derek and Andrew, 1994). Molecular genetics has allowed 
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the identification of certain specific and clinically identifiable forms of type II 
diabetes that are the result of single gene defects. The majority of cases of type II 
diabetes are multifactorial in nature, with interactions from environmental and 
genetic factors (Christopher et al., 1999). The nature of the genetic contribution is 
largely unknown but it is evident that several genes are involved. In this polygenic 
model the inheritance of abnormalities in individual genes would not be sufficient to 
cause type II diabetes directly, but it would confer increased (or decreased) 
susceptibility. Also, age is an important risk factor for type II diabetes. In Britain, 
over 70% of all cases of diabetes occur after the age of 50 years. Type II diabetes is 
principally a disease of the middle-aged and elderly, affecting 10% of the population 
over the age of 65 (Christopher et al., 1999).  
 
1.4. Diabetes in Malaysia 
Malaysia is a multiethnic country with a total population of 28.25 million 
(Department of Statistics Malaysia, 2010). According to the third national health and 
morbidity survey (NHMS-3) in Malaysia, the prevalence of type II diabetes mellitus 
in adults aged 30 years and over now stands at 14.9%, increased from 8.3% in 1996, 
with the highest prevalence among those of Indian ethnicity (National Health and 
Morbidity Survey III, 2006). The number of people with diabetes is expected to 
increase from 1,846,000 in 2010 to 3,254,994 in 2030, and the adjusted prevalence of 
diabetes (adjusted to the world population) in Malaysia will rise from 11.6% in 2010 
to 13.8% in 2030 (International Diabetes Federation, 2009). In the Malaysian 
Ministry of Health, there is an increasing interest in the increasing prevalence of 
chronic disease, including diabetes, within the population (Lim and Lim, 2006). This 
increase in prevalence of diabetes is associated with many factors, including rapid 
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economic growth of the country in the last few decades, urbanization and 
industrialization which have resulted in more overweight/obese people and a 
sedentary population (Ismail et al., 2002; Kee et al., 2008; Mustaffa, 2004). A 
skyrocketing transformation in socioeconomic and demographic status over the last 
two decades has occurred in Malaysia as a result of massive industrialization and 
globalization with an improved educational system. As a result, the standard of 
living, quality of life, population and the concomitant ageing of the population and 
reduction in the death rate have improved (Yun et al., 2007). The percentage of 
Malaysia people over the age 65 of years has increased annually by an average of 
2.5% between 1991 and 2000 (Poi et al., 2004). In this age group, around 25% to 
30% of people have diabetes or glucose intolerance (Wild et al., 2004). In the 
Malaysian burden of disease and injury study (Faudzi, et al., 2004), it was estimated 
that for year 2000, there were 2,261 deaths attributed to diabetes (857 men and 1404 
women). Although diabetes was not in the top 10 causes of highest years of life lost 
(YLL) in men, the disease incurred a huge burden in terms of non-fatal disability, i.e. 
morbidity measured as years lived with disability (YLD). Diabetes was ranked third 
at 34,750 years in the men. The scenario was worst for women; scoring higher for 
both indexes; 18,759 years for YLL and 37,631 years for YLD. This means, 
Malaysian women with diabetes die faster, and those who survived, had to endure 
more sufferings. The simple mathematical addition of YLL + YLD yielded yet 
another index; the disability adjusted life years (DALYs), is a composite measure of 
burden of premature mortality and non-fatal health outcome (morbidity). Based on 
DALYs, among the top 10 total burden of disease in Malaysia, diabetes was ranked 
6th for men and 5th for women. Despite its lower ranking, diabetes probably 
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contributed significantly to the causality of the higher ranking diseases with the 
exception of unipolar major depression (Faudzi, et al., 2004).  
 
1.5. Oral antidiabetic drugs 
Increasing knowledge about the molecules involved in β-cell functions provides 
potential new targets for drug development. The aims of the treatment of type II 
diabetes are to alleviate symptoms through the normalization or near-normalization 
of fasting and postprandial blood glucose levels and to prevent acute and long-term 
complications. Intensive treatment of type I diabetes prevents the development of 
microvascular and neurological complications, and most likely will do the same in 
type II diabetes (Ohkubo et al., 1995). There are various pharmacological approaches 
for improving glucose homeostasis but the ones that are currently being used in 
clinical practice either do not succeed in restoring normoglycemia in most patients or 
they fail after variable periods of time. Four classes of drugs are currently available 
for glycemic regulation: sulphonylureas, for example glibenclamide; biguanides, for 
example metformin; α-glucosidase inhibitors, for example acarbose; and insulin, 
each of which has a different mode and site of action. These standard 
pharmacological treatments can be used individually for certain types of patients or 
they can be combined in a stepwise fashion to provide a more ideal glycemic control 
in these patients (Gerard et al., 1999). 
 
1.5.1. Sulphonylureas 
The first generation of sulphonylureas, including such compounds as 
chlorpropamide, acetohexamide, tolazamide and tolbutamide, were developed and 
introduced into clinical use in the 1950s. More potent second-generation agents, such 
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as glibenclamide (glyburide), glipizide and gliclazide, were developed during the late 
1960s and 1970s. There are differences between the various sulphonylureas with 
respect to their duration of action, adverse effects, potency and metabolism (Holman 
and Turner, 1991). The chemical differences are responsible for pharmacokinetic 
differences. All sulphonylureas act by stimulating pancreatic β-cells to secrete 
insulin. They bind to β-cell receptors, which are closely associated with ATP-
dependent K+ channels; the closure of these channels causes depolarization of the 
cell, an influx of Ca2+ and the stimulation of insulin secretion (Groop, 1992; Aguilar-
Bryan et al., 1995). All sulphonylureas directly stimulate insulin secretion but, more 
importantly, they also augment glucose-induced insulin secretion. Insulin release is 
normally biphasic. An early peak occurs during the first few minutes of glucose-
induced stimulation, after which there is a slower, more sustained second phase. In 
common with tolbutamide, gliclazide mainly stimulates the early peak of insulin 
secretion, whereas other sulphonylureas, such as glibenclamide and chlorpropamide, 
largely exert their insulin secretory effects during the second phase (Melander et al., 
1989). 
 
The timing of medication depends on the pharmacokinetics of the individual 
sulphonylurea, but taking a dose 30 min before breakfast will usually produce 
optimal control. Sulphonylureas with a short half-life, especially tolbutamide, should 
be taken immediately before meals. Primary failure implies that there is severe β-cell 
dysfunction. Patients with higher fasting blood glucose levels (usually >14 mmol/L) 
or ketonuria at diagnosis are unlikely to respond to initial sulphonylurea treatment 
and will require insulin. Mutations in the sulphonylurea receptors have yet to be 
implicated as a mechanism for primary drug failure (Aguilar-Bryan et al., 1995; 
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Inoue et al., 1996). Sulphonylurea failure is a term used to denote the presence of 
symptomatic hyperglycemia despite treatment or following a symptom-free period of 
time (secondary sulphonylurea failure) (Holman and Turner, 1991). The occurrence 
of secondary failure implies that the sulphonylurea is no longer effective. The 
clinical efficacy of sulphonylurea is greatest in patients with type II diabetes of 5 
years duration or less. The secondary failure rate has been reported to be as high as 
3-5% per year (Groop, 1992; Lebovitz, 1994; Pontiroli et al., 1994). The issue of 
efficacy is complicated by patient noncompliance, the use of inadequate drug doses 
and by other confounding factors (Groop, 1992; Pontiroli et al., 1994). Profound 
hypoglycemia is the major adverse effect associated with all sulphonylureas. This is 
particularly evident in the case of chlorpropamide, which has a long duration of 
action; for this reason, caution is needed when this drug is taken by aged patients or 
patients with renal insufficiency. Another adverse effect of sulphonylureas is a gain 
in body weight. The anabolic effects of increased insulin levels together with reduced 
urinary losses of glucose can contribute to such a weight increase. Sulphonylureas 
have no stimulatory effect on insulin secretion in patients with insulin-dependent 
diabetes mellitus or in patients with pancreatectomized diabetes since successful 
therapy requires a functioning insulin secretory system (Jackson and Bressler, 1981).  
 
1.5.2. Biguanides 
The biguanide metformin alleviates hyperglycemia from type II diabetes by 
inhibiting hepatic glucose production and improving peripheral insulin sensitivity. In 
contrast to sulphonylureas, metformin does not stimulate insulin secretion, promote 
weight gain, exacerbate hyperinsulinemia or cause hypoglycemia. It also favorably 
affects serum lipids. Metformin can be used as first-line monotherapy in type II 
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diabetes or in combination with a sulphonylurea when monotherapy with either agent 
fails (Guthrie, 1997). It can be particularly suitable when weight gain, 
hyperlipidemia and hypoglycemia are clinically important issues. Pharmacological 
studies have indicated that metformin acts by improving peripheral tissue sensitivity 
to insulin, reducing the gastrointestinal absorption of glucose and decreasing hepatic 
glucose production (Klip and Leiter, 1990; Bailey, 1992). A decrease in total plasma 
cholesterol, low-density lipoprotein cholesterol and triglyceride levels and an 
increase in high-density lipoprotein cholesterol levels were reported (Bailey, 1993; 
Defronzo et al., 1995; Stumvoll et al., 1995). Metformin lowers elevated blood 
glucose levels, but it does not normally cause hypoglycemia. It can actually reduce 
insulin levels and, in most cases, this is secondary to its glucose-lowering effects and 
not a direct action of the drug (Hermann and Melander, 1992; United Kingdom 
Prospective Diabetes Study Group, 1995). Tucker et al. (1981) reported that 
metformin at doses of 0.5-1.5 g has an absolute oral bioavailability of 50-60%, and 
that its gastrointestinal absorption is complete within 6 hours of ingestion. It has a 
mean plasma elimination half-life of 1.5-4.7 hours. This is prolonged in patients with 
impaired renal function and correlates with creatinine clearance. Drug interactions 
with metformin are infrequent. Metformin monotherapy (0.5-3 g/day) was shown to 
reduce fasting blood glucose concentrations (by 22-26% of pretreatment levels) and 
glycated hemoglobin (by 12-17% of pretreatment levels, which represents a fall in 
glycated hemoglobin from 1.4 to 1.8%) to a significantly greater extent than a 
placebo in controlled clinical studies of up to 8 months duration in patients with type 
II diabetes mellitus poorly controlled by diet alone (Dornan et al., 1991; Noury and 
Nandeuil, 1991; Defronzo et al., 1995).   
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1.5.3. α-glucosidase inhibitors  
α-glucosidase inhibitors are competitive inhibitors of small intestinal α-glucosidase 
enzymes that break down non-absorbable oligosaccharides (Balfour and McTavish, 
1993) only commercialized α-glucosidase inhibitor is acarbose. Chemically, acarbose 
is an oligosaccharide produced by cultured strains of actinomycetes. It is a 
competitive inhibitor with a high affinity for sucrase and a lower affinity for 
glucoamylase and pancreatic α-amylase (Taylor, 1990). It is administered with food 
and must be ingested three or more times per day. When patients ingest meals 
containing sucrose or starch, acarbose decreases the postprandial rise in blood 
glucose levels (Taylor, 1990). The activity of acarbose is non-systemic. Clinical 
studies of acarbose in patients with both type I and type II diabetes have shown 
decreases in postprandial blood glucose concentrations and urinary glucose excretion 
(Requejo et al., 1990; Chiasson et al., 1994). The improvement in blood glucose 
control is modest (Taylor, 1990). Overall, acarbose has the advantage that when it is 
used as monotherapy it never causes hypoglycemia. The major adverse effects of 
acarbose are on the gastrointestinal system, particularly flatulence, abdominal 
bloating, borborygmus and sometimes diarrhea (Hotta et al., 1993).  
 
1.5.4. Thiazolinediones 
Recently, a new class of insulin-sensitizing agents, the thiazolinediones, has caused 
much interest. Thiazolinedions are insulin action enhancers that appear to improve 
glucose tolerance, decrease hepatic glucose production and increase insulin-
stimulated glucose disposal (Saltiel and Horikashi, 1995). In an attempt to 
understand their mechanism of action, thiazolinedions were observed to bind with 
high affinity and activate a nuclear hormone receptor called peroxisome proliferator-
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activated receptor γ (PPARγ). The ligand that binds naturally to PPARγ has not been 
identified, but it is believed that the PPARγ receptor is potentially important in 
promoting the differentiation of fat cells (Tontonoz et al., 1994). One of the factors 
that control fat cell differentiation is the switching on of genes that mediate insulin 
action. Accordingly, the stimulation of PPARγ has been shown to turn on the 
expression of several genes involved in glucose and lipid metabolism. Several 
thiazolinedione compounds have been developed (e.g., pioglitazone, darglitazone, 
BRL-49653). One of these agents, troglitazone (Rezulin®, approved by the Food and 
Drug Administration on January 29, 1997), was evaluated in patients with type II 
diabetes and found to be efficacious and safe (Ciaraldi et al., 1990; Colca and 
Morton, 1990). The efficacy of troglitazone in patients with type II diabetes has been 
demonstrated in a substantial number of clinical studies (Suter et al., 1992). 
Troglitazone is rapidly absorbed from the gastrointestinal tract; peak blood levels 
occur within 2-3 hours. It should be taken with meals because food increases its 
absorption by 30-85%. The use of oral troglitazone has been shown to result in a 
decrease in fasting and postprandial blood glucose levels (Iwamoto et al., 1996). 
Treated diabetic patients showed improved glucose tolerance test results, decreased 
plasma free fatty acid and triglyceride levels, decreased plasma insulin levels, 
decreased gluconeogenesis and increased glucose disposal (Suter et al., 1992; 
Mimura et al., 1994).  
 
1.5.5. Dipeptidyl peptidase (DPP)-IV  
Dipeptidyl peptidase (DPP)-IV inhibitors, which act via enhancing the incretins, 
represent another new therapeutic approach to the treatment of type 2 diabetes. 
Glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic peptide (GIP) 
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account for the majority of incretin action (Drucker 2003a). GLP-1 is a gut hormone 
that plays a key role in glucose homeostasis via its incretin effect. GLP-1 is produced 
from the enteroendocrine L-cell of small intestine and is secreted in response to meal 
and nutrients. It stimulates insulin release from the pancreatic islets in a glucose 
dependent manner. It restores the defective first and second phases of insulin 
response to glucose in type 2 diabetes patients (Fehse et al., 2005 and Nauck et al., 
1993). Moreover, GLP-1 suppresses post-prandial glucagon release, delay gastric 
emptying and increase satiety (Drucker 2002; Nauck 1997and Kieffer and Habener 
1999). 
 
The therapeutic potential of native GLP-1 is limited by its short physiologic half-life, 
owing to its rapid inactivation by the enzyme DPP-IV and to renal clearance. As 
such, several selective inhibitors of DPP-IV are being developed for the treatment of 
type II diabetes mellitus (Drucker 2003b). These orally administered DPP-IV 
inhibitors can increase circulating levels of endogenous GLP-1 and GIP and improve 
glucose homeostasis in human subjects with type II diabetes mellitus (Herman et al., 
2005 and Ahren et al., 2004). At the American Diabetes Association (ADA) 
66th Scientific Sessions, considerable new data were presented on the actions of these 
agents in preclinical studies and in patients with type II diabetes mellitus (66th). This 
report discusses the most clinically relevant data presented at this meeting pertaining 
to the DPP-IV inhibitors sitagliptin (MK-0431) and vildagliptin (LAF-237). 
 
 
 
 
  
 
20
1.5.5.1. Sitagliptin 
In October 2006, sitagliptin became the first DPP-IV inhibitor to gain food and drug 
administration (FDA) approval for the treatment of type 2 diabetes. Sitagliptin tablets 
are commercially available as 100-mg (beige), 50-mg (light beige), and 25-mg (pink) 
tablets. Sitagliptin is also available in a combination product with metformin in doses 
of 50 mg sitagliptin/500 mg metformin and 50 mg sitagliptin/1,000 mg metformin 
(White 2008). The clinical efficacy and tolerability of sitagliptin were evaluated in 
monotherapy and in combination with established antidiabetic agents. A 12-week, 
randomized, double-blind study compared sitagliptin 100 mg once daily (n = 75) 
with placebo (n = 76) in Japanese patients with type II diabetes mellitus (after 
washout of antidiabetic medications). Mean baseline A1C was 7.5% in the 
sitagliptin-treated group. At week 12, there was a between-treatment group 
difference in A1C of -1.05% (95% confidence interval: -1.27, -0.84), favoring 
sitagliptin, with 58.1% of patients on sitagliptin achieving an A1C of < 7% compared 
with 14.5% on placebo. The incidence of adverse events was similar between the 
groups, with no hypoglycemia and body weight unchanged in the sitagliptin arm 
(Nonaka et al., 2006). Another monotherapy study Raz et al (2006) randomized 521 
patients with type II diabetes mellitus (mean A1C 8.1%) to placebo, sitagliptin 100 
mg once daily, or sitagliptin 200 mg once daily for 18 weeks. Compared with 
placebo, the reduction in A1C was 0.60% greater with sitagliptin 100 mg and 0.48% 
greater with sitagliptin 200 mg, respectively. Fasting glucose similarly showed 
significant reduction with sitagliptin. In addition, sitagliptin 100 mg was associated 
with improvement in both the fasting proinsulin/insulin ratio and homeostasis model 
of assessment of beta-cell function (HOMA-B), suggestive of beneficial effects on 
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beta-cell function. These data support the possibility of using this DPP-IV inhibitor 
in combination therapy with other antidiabetic agents (Raz et al., 2006). 
 
1.5.5.2. Vildagliptin 
Vildagliptin (Glavus®) is a DPP-IV inhibitor, has completed phase iii clinical 
development and awaiting FDA approval for marketing. A series of studies evaluated 
the clinical efficacy and tolerability of vildagliptin in patients with type II diabetes 
mellitus. In a 52-week, randomized, double-blind study (Dejager et al., 2006) 
comparing vildagliptin 50 mg twice daily (n = 526) with metformin 1000 mg twice 
daily (n = 254) in drug-naive patients with type II diabetes mellitus (mean baseline 
glycated hemoglobin [A1C], 8.7%), the adjusted mean change in A1C from baseline 
to endpoint was -1.0 ± 0.1% in patients receiving vildagliptin and -1.4 ± 0.1% in 
those receiving metformin. Although this result did not establish noninferiority of 
vildagliptin relative to metformin as monotherapy, it did demonstrate an early (by 12 
weeks) and sustained (over 1 year) reduction in A1C with this DPP-IV inhibitor. In 
addition, vildagliptin therapy was not associated with weight gain and was well 
tolerated, with a lower incidence of gastrointestinal side effects than was observed 
with metformin (21.8% vs 43.7%, P < .001) and no significant hypoglycemia. The 
mechanisms underlying the glucose-lowering activity of vildagliptin were 
investigated in several studies. Beta-cell function was evaluated in a 12-week study 
(D'Alessio et al., 2006)   comparing vildagliptin (50 mg twice daily, n = 7) and 
placebo (n = 5) in drug-naive patients with type II diabetes mellitus (mean A1C 6.8% 
± 0.1%). Participants underwent frequently sampled intravenous glucose tolerance 
tests at baseline, after 12 weeks of treatment, and after 2-4 weeks of washout from 
study drug. Vildagliptin was associated with significant increases in the acute insulin 
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response to glucose (AIRg) and insulin sensitivity (IS), such that the disposition 
index (AIRg x IS), a measure of beta-cell compensation for ambient insulin 
resistance, increased by more than 4-fold during vildagliptin treatment. Furthermore, 
it is intriguing to note that some of the improvement in beta-cell function was 
maintained after the 2- to 4-week washout period, suggesting that vildagliptin 
exhibits the potential to exert a disease-modifying effect (D'Alessio et al., 2006). 
 
1.6. Objective 
The direction of the present study was aimed on the influence of ethanolic extract of 
O. stamineus on all major attractive targets of diabetes intended to act on decrease 
the hyperglycemia, countering insulin resistance, insulin sensitivity, α-glucosidase 
and α-amylase inhibitory potential and the safety use of O. stamineus by focusing on 
the acute and 28-days sub-chronic toxicity. This would help the research on O. 
stamineus advance further and throw some light on previously unknown details.    
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CHAPTER TWO: The antihyperglycemic effect of a single dose administration 
of ethanolic extracts of O. stamineus Benth in Sprague-
Dawley rats and their activity-guided fractionation 
 
2. Introduction  
In vivo or whole animal models play an important part in pharmacological research, 
especially in preliminary bioactivity studies. Since the results of in vitro studies need 
to be supported and verified by in vivo findings, proper models must be chosen 
wisely. A scientific model is not a complete representation of human 
pathophysiology but merely a scientific analogy. In a preliminary screening study the 
model should be simple and reliable. The parameters should be objectively 
measurable in order to ensure easy replication and to provide a reliable guide for 
follow-up studies, especially in bioactivity-guided isolation studies. Two test 
methods were used in the present study; namely, hypoglycemic and intraperitoneal 
glucose tolerance tests. The latter was basically a modification of the oral glucose 
tolerance test in humans.  
 
O. stamineus is traditionally used in the treatment of type II diabetes mellitus and is 
usually taken orally in the form of a water concoction (Bwin and Gwan, 1967). 
Sriplang et al. (2007) found that O. stamineus aqueous extracts reduced 
hyperglycemia, decreased plasma triglyceride and increased plasma HDL-cholesterol 
concentrations in STZ-induced diabetic rats. An antihyperglycemic effect of the 80% 
ethanolic extract of the plant was observed in normal and diabetic rats after acute and 
repeated daily dose administrations (Zhang and Tan, 2000). However, Mariam et al. 
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(1996) reported that a 1 g/kg aqueous extract of this plant reduced the blood glucose 
levels in both normal and STZ-induced diabetic rats. A hypoglycemic agent is an 
agent that has the ability to reduce blood glucose levels to below normal fasting 
levels, for example the antidiabetic drug glibenclamide, whereas an 
antihyperglycemic agent lowers the blood glucose level but not to below the normal 
fasting level, for example metformin (Nolte and Karam, 2001). Using these two 
clinically proven antidiabetic drugs in animal models as reference drugs helps to 
maintain the relevancy of the models.  
 
In vivo experiments play an important role in the pharmacological screening of new 
drugs, especially in preliminary bioactivity studies. This is especially true where a 
preliminary in vitro result requires further in vivo testing to be carried out. Therefore, 
both in vitro and in vivo tests are important methods for screening the unknown 
pharmacological effects of a drug and for characterizing the range of its activities. 
The results of in vivo tests are anything but obvious because of the simple reason that 
in vitro tests are usually performed using isolated tissues or simulated conditions that 
do not completely relate to human pathophysiology. Thus, the effects of new drugs 
or plant extracts should be further demonstrated in whole live animals with simulated 
disease conditions. 
 
In addition, as these two tests are capable of screening for hypoglycemic and 
antihyperglycemic agents they are also useful for preventing any false-negative or 
false-positive findings in the screening of plants with antidiabetic actions. Therefore, 
the aims of the present study were to examine the antihyperglycemic and 
hypoglycemic effects of O. stamineus extracts with different solvent ratios of 
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ethanol-water mixture. In this study different percentages of ethanol in water were 
used as solvents to prepare extracts of O. stamineus for preliminary bioactivity 
screening. The solvents used were 95%, 75%, 50% and 25% ethanol v/v in water. 
The extraction of active compounds from the plant into these solvents would be 
dependent on their polarity; compounds having same polarity would become 
concentrated in same polarity solvents. 
 
2.1. Objectives  
- To verify the validity of the hypoglycemic and antihyperglycemic screening model 
employed.  
- To utilize the hypoglycemic and subcutaneous glucose tolerance tests (SCGTT) for 
screening the effects of 95%, 75%, 50% and 25% ethanol/water extracts of O. 
stamineus. 
- To perform SCGTT-guided fractionation on the active extracts of O. stamineus in 
normal and STZ-induced diabetic rats. 
 
2.2. Materials and methods  
2.2.1. Plant material and preparation of the extracts 
Dried leaves of O. stamineus were collected from Kepala Batas, Pulau Pinang 
Malaysia. The plant was identified at the School of Biological Sciences, Universiti 
Sains Malaysia, and a voucher specimen (10810) was deposited at the Herbarium of 
School of Biological Sciences, Universiti Sains Malaysia. The dried leaves were 
powdered using a milling machine and then divided into four equal portions and 
extracted with 95%, 75%, 50% and 25% water/ethanol, v/v, respectively. The 
ethanol solvent was supplied by R&M Chemical Sdn Bhd as 95% v/v denatured 
